Maria Paola Costi

List of Publications by Year in Descending Order

127 papers	2,585 citations	27 h-index	43 g-index
149 ext. papers	2,985 ext. citations	5.8 avg, IF	4.52 L-index

#	Paper	IF	Citations
127	Intrinsic Fluorometric Reporters of Pteridine Reductase 1, a Target for Antiparasitic Agents. *Physchem*, **2022**, 2, 131-144		
126	Intrinsic Fluorescence of the Active and the Inactive Functional Forms of Human Thymidylate Synthase. *ChemBioChem*, **2021**, 22, 1800-1810	3.8	1
125	Folic Acid-Peptide Conjugates Combine Selective Cancer Cell Internalization with Thymidylate Synthase Dimer Interface Targeting. *Journal of Medicinal Chemistry*, **2021**, 64, 3204-3221	8.3	4
124	High-resolution crystal structure of Trypanosoma brucei pteridine reductase 1 in complex with an innovative tricyclic-based inhibitor. *Acta Crystallographica Section D: Structural Biology*, **2020**, 76, 558-564	5.5	1
123	A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	3
122	Designing Chimeric Molecules for Drug Discovery by Leveraging Chemical Biology. *Journal of Medicinal Chemistry*, **2020**, 63, 1908-1928	8.3	14
121	Identification of a 2,4-diaminopyrimidine scaffold targeting Trypanosoma brucei pteridine reductase 1 from the LIBRA compound library screening campaign. *European Journal of Medicinal Chemistry*, **2020**, 189, 112047	6.8	3
120	Virtual screening identifies broad-spectrum β-lactamase inhibitors with activity on clinically relevant serine- and metallo-carbapenemases. *Scientific Reports*, **2020**, 10, 12763	4.9	12
119	Cyclic Peptides Acting as Allosteric Inhibitors of Human Thymidylate Synthase and Cancer Cell Growth. *Molecules*, **2019**, 24,	4.8	2
118	Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics. *European Journal of Medicinal Chemistry*, **2019**, 183, 111676	6.8	10
117	SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti- Agent. *ACS Medicinal Chemistry Letters*, **2019**, 10, 528-533	4.3	3
116	Structural Comparison of and Human Thymidylate Synthase Complexes with the Substrate dUMP and Its Analogue FdUMP Provides Hints about Enzyme Conformational Variabilities. *Molecules*, **2019**, 24,	4.8	11
115	Structural Insights into the Development of Cycloguanil Derivatives as Pteridine-Reductase-1 Inhibitors. *ACS Infectious Diseases*, **2019**, 5, 1105-1114	5.5	4
114	Optimization of N-alkylation in the Synthesis of Methotrexate and Pteridine-based Derivatives Under Microwave-Irradiation. *ChemistrySelect*, **2019**, 4, 4429-4433	1.8	3
113	Evidence of Destabilization of the Human Thymidylate Synthase (hTS) Dimeric Structure Induced by the Interface Mutation Q62R. *Biomolecules*, **2019**, 9,	5.9	1
112	Excited-state intramolecular proton transfer in a bioactive flavonoid provides fluorescence observables for recognizing its engagement with target proteins. *Photochemical and Photobiological Sciences*, **2019**, 18, 2270-2280	4.2	4
111	Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections. *Journal of Medicinal Chemistry*, **2019**, 62, 3989-4012	8.3	11

110	X-ray Crystallography Deciphers the Activity of Broad-Spectrum Boronic Acid β-Lactamase Inhibitors. *ACS Medicinal Chemistry Letters*, **2019**, 10, 650-655	4.3	22
109	Structural and Functional Characterization of the Human Thymidylate Synthase (hTS) Interface Variant R175C, New Perspectives for the Development of hTS Inhibitors. *Molecules*, **2019**, 24,	4.8	1
108	Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform. *SLAS Discovery*, **2019**, 24, 346-361	3.4	9
107	The 1,10-Phenanthroline Ligand Enhances the Antiproliferative Activity of DNA-Intercalating Thiourea-Pd(II) and -Pt(II) Complexes Against Cisplatin-Sensitive and -Resistant Human Ovarian Cancer Cell Lines. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	3
106	Development of a Focused Library of Triazole-Linked Privileged-Structure-Based Conjugates Leading to the Discovery of Novel Phenotypic Hits against Protozoan Parasitic Infections. *ChemMedChem*, **2018**, 13, 678-683	3.7	11
105	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. *European Journal of Medicinal Chemistry*, **2018**, 146, 423-434	6.8	19
104	Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer. *Frontiers in Pharmacology*, **2018**, 9, 454	5.6	6
103	Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth. *Journal of Medicinal Chemistry*, **2018**, 61, 7374-7380	8.3	5
102	Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth. *Vitamins and Hormones*, **2018**, 107, 473-513	2.5	9
101	Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR). *European Journal of Medicinal Chemistry*, **2018**, 155, 229-243	6.8	12
100	Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer. *BMC Cancer*, **2018**, 18, 1267	4.8	6
99	Scaffolds and Biological Targets Avenue to Fight Against Drug Resistance in Leishmaniasis. *Annual Reports in Medicinal Chemistry*, **2018**, 51, 39-95	1.6	4
98	Repurposing of Drugs Targeting YAP-TEAD Functions. *Cancers*, **2018**, 10,	6.6	18
97	pH-Promoted Release of a Novel Anti-Tumour Peptide by "Stealth" Liposomes: Effect of Nanocarriers on the Drug Activity in Cis-Platinum Resistant Cancer Cells. *Pharmaceutical Research*, **2018**, 35, 206	4.5	8
96	Molecular basis for covalent inhibition of glyceraldehyde-3-phosphate dehydrogenase by a 2-phenoxy-1,4-naphthoquinone small molecule. *Chemical Biology and Drug Design*, **2017**, 90, 225-235	2.9	12
95	Design, synthesis and biological evaluation of non-covalent AmpC β-lactamases inhibitors. *Medicinal Chemistry Research*, **2017**, 26, 975-986	2.2	9
94	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus. *European Journal of Medicinal Chemistry*, **2017**, 135, 467-478	6.8	20
93	The Future of Drug Development for Neglected Tropical Diseases: How the European Commission Can Continue to Make a Difference. *Trends in Parasitology*, **2017**, 33, 581-583	6.4	8

92	Methoxylated 2Thydroxychalcones as antiparasitic hit compounds. *European Journal of Medicinal Chemistry*, **2017**, 126, 1129-1135	6.8	17
91	Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity. *European Journal of Medicinal Chemistry*, **2017**, 141, 138-148	6.8	17
90	Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To Inhibit Pteridine Reductase in Support of Early-Stage Drug Discovery. *ACS Omega*, **2017**, 2, 5666-5683	3.9	17
89	Comparative mapping of on-targets and off-targets for the discovery of anti-trypanosomatid folate pathway inhibitors. *Biochimica Et Biophysica Acta - General Subjects*, **2017**, 1861, 3215-3230	4	8
88	TRAP1: a viable therapeutic target for future cancer treatments?. *Expert Opinion on Therapeutic Targets*, **2017**, 21, 805-815	6.4	24
87	Conveying a newly designed hydrophilic anti-human thymidylate synthase peptide to cisplatin resistant cancer cells: are pH-sensitive liposomes more effective than conventional ones?. *Drug Development and Industrial Pharmacy*, **2017**, 43, 465-473	3.6	9
86	Target-based approaches for the discovery of new antimycobacterial drugs. *Drug Discovery Today*, **2017**, 22, 576-584	8.8	18
85	Computational and biological profile of boronic acids for the detection of bacterial serine- and metallo-lactamases. *Scientific Reports*, **2017**, 7, 17716	4.9	23
84	Label-free fiber optic optrode for the detection of class C lactamases expressed by drug resistant bacteria. *Biomedical Optics Express*, **2017**, 8, 5191-5205	3.5	16
83	Chroman-4-One Derivatives Targeting Pteridine Reductase 1 and Showing Anti-Parasitic Activity. *Molecules*, **2017**, 22,	4.8	25
82	In Silico Identification and In Vitro Evaluation of Natural Inhibitors of Leishmania major Pteridine Reductase I. *Molecules*, **2017**, 22,	4.8	7
81	Design, Synthesis and StructureActivity Relationships of a Phenotypic Small Library against Protozoan Infections. *Proceedings (mdpi)*, **2017**, 1, 648	0.3	2
80	Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate Synthase Case. *ChemMedChem*, **2016**, 11, 1653-66	3.7	12
79	Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs. *Journal of Medicinal Chemistry*, **2016**, 59, 7598-616	8.3	30
78	Intracellular quantitative detection of human thymidylate synthase engagement with an unconventional inhibitor using tetracysteine-diarsenical-probe technology. *Scientific Reports*, **2016**, 6, 27198	4.9	10
77	Decoding the Structural Basis For Carbapenem Hydrolysis By Class A lactamases: Fishing For A Pharmacophore. *Current Drug Targets*, **2016**, 17, 983-1005	3	24
76	Virtual Screening and X-ray Crystallography Identify Non-Substrate Analog Inhibitors of Flavin-Dependent Thymidylate Synthase. *Journal of Medicinal Chemistry*, **2016**, 59, 9269-9275	8.3	16
75	Hotspots in an obligate homodimeric anticancer target. Structural and functional effects of interfacial mutations in human thymidylate synthase. *Journal of Medicinal Chemistry*, **2015**, 58, 3572-81	8.3	18

74	Enhanced anti-hyperproliferative activity of human thymidylate synthase inhibitor peptide by solid lipid nanoparticle delivery. *Colloids and Surfaces B: Biointerfaces*, **2015**, 136, 346-54	6	14
73	Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance. *Drug Resistance Updates*, **2015**, 23, 20-54	23.2	38
72	2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1. *ACS Chemical Biology*, **2015**, 10, 705-14	4.9	95
71	The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment. *Journal of Medicinal Chemistry*, **2015**, 58, 4857-73	8.3	109
70	Alanine mutants of the interface residues of human thymidylate synthase decode key features of the binding mode of allosteric anticancer peptides. *Journal of Medicinal Chemistry*, **2015**, 58, 1012-8	8.3	9
69	2-[N-Alkyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines as anticancer agents inhibitors of folate enzymes. *European Journal of Medicinal Chemistry*, **2014**, 75, 169-83	6.8	7
68	Internalization and stability of a thymidylate synthase Peptide inhibitor in ovarian cancer cells. *Journal of Medicinal Chemistry*, **2014**, 57, 10551-6	8.3	9
67	Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth. *Journal of Medicinal Chemistry*, **2014**, 57, 1355-67	8.3	17
66	Mass spectrometric/bioinformatic identification of a protein subset that characterizes the cellular activity of anticancer peptides. *Journal of Proteome Research*, **2014**, 13, 5250-61	5.6	11
65	Targeting class A and C serine □lactamases with a broad-spectrum boronic acid derivative. *Journal of Medicinal Chemistry*, **2014**, 57, 5449-58	8.3	39
64	The inhibition of extended spectrum □lactamases: hits and leads. *Current Medicinal Chemistry*, **2014**, 21, 1405-34	4.3	20
63	Ligand-based discovery of N-(1,3-dioxo-1H,3H-benzo[de]isochromen-5-yl)-carboxamide and sulfonamide derivatives as thymidylate synthase A inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 663-8	2.9	8
62	2□Deoxyuridine 5□monophosphate substrate displacement in thymidylate synthase through 6-hydroxy-2H-naphtho[1,8-bc]furan-2-one derivatives. *Journal of Medicinal Chemistry*, **2013**, 56, 9356-60	8.3	6
61	Biochemical effects of riluzole on Leishmania parasites. *Experimental Parasitology*, **2013**, 133, 250-4	2.1	6
60	Targeting the Trypanosomatidic Enzymes Pteridine Reductase and Dihydrofolate Reductase **2013**, 445-472		2
59	Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity. *Scientific Reports*, **2013**, 3, 1035	4.9	110
58	Translational repression of thymidylate synthase by targeting its mRNA. *Nucleic Acids Research*, **2013**, 41, 4159-70	20.1	8
57	Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and -resistant human ovarian cancer cells. *International Journal of Oncology*, **2013**, 43, 1269-80	4.4	36

56	Protein-Protein Interaction Inhibitors: Case Studies on Small Molecules and Natural Compounds **2013**, 31-60		5
55	Distamycin A and derivatives as synergic drugs in cisplatin-sensitive and -resistant ovarian cancer cells. *Amino Acids*, **2012**, 42, 641-53	3.5	8
54	Inhibitor of ovarian cancer cells growth by virtual screening: a new thiazole derivative targeting human thymidylate synthase. *Journal of Medicinal Chemistry*, **2012**, 55, 10272-6	8.3	18
53	The structure of Enterococcus faecalis thymidylate synthase provides clues about folate bacterial metabolism. *Acta Crystallographica Section D: Biological Crystallography*, **2012**, 68, 1232-41		22
52	Structure-based selectivity optimization of piperidine-pteridine derivatives as potent Leishmania pteridine reductase inhibitors. *Journal of Medicinal Chemistry*, **2012**, 55, 8318-29	8.3	35
51	Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines. *Investigational New Drugs*, **2012**, 30, 1484-92	4.3	6
50	Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase. *Journal of Medicinal Chemistry*, **2011**, 54, 211-21	8.3	52
49	Permeation through the cell membrane of a boron-based β-lactamase inhibitor. *PLoS ONE*, **2011**, 6, e23187	3.7	16
48	Identification of the binding modes of N-phenylphthalimides inhibiting bacterial thymidylate synthase through X-ray crystallography screening. *Journal of Medicinal Chemistry*, **2011**, 54, 5454-67	8.3	13
47	Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, E542-9	11.5	66
46	Design and characterization of a mutation outside the active site of human thymidylate synthase that affects ligand binding. *Protein Engineering, Design and Selection*, **2010**, 23, 81-9	1.9	5
45	Homodimeric enzymes as drug targets. *Current Medicinal Chemistry*, **2010**, 17, 826-46	4.3	37
44	Novel approaches for targeting thymidylate synthase to overcome the resistance and toxicity of anticancer drugs. *Journal of Medicinal Chemistry*, **2010**, 53, 6539-49	8.3	38
43	Spermidine/spermine N1-acetyltranferase modulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistant human ovarian cancer cell lines. *Gynecologic Oncology*, **2010**, 117, 202-10	4.9	9
42	Structural study of phenyl boronic acid derivatives as AmpC beta-lactamase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 3416-9	2.9	31
41	Ligand-based virtual screening and ADME-tox guided approach to identify triazolo-quinoxalines as folate cycle inhibitors. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 7773-85	3.4	20
40	Dimer-monomer equilibrium of human thymidylate synthase monitored by fluorescence resonance energy transfer. *Protein Science*, **2010**, 19, 1023-30	6.3	15
39	Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells. *European Journal of Pharmacology*, **2009**, 615, 17-26	5.3	27

38	Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. *Journal of Medicinal Chemistry*, **2008**, 51, 2502-11	8.3	136
37	Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 1448-53	11.5	106
36	Constrained dansyl derivatives reveal bacterial specificity of highly conserved thymidylate synthases. *ChemBioChem*, **2008**, 9, 779-90	3.8	4
35	Sequence-based identification of specific drug target regions in the thymidylate synthase enzyme family. *ChemMedChem*, **2008**, 3, 392-401	3.7	11
34	Synthesis of N-(5,7-diamino-3-phenyl-quinoxalin-2-yl)-3,4,5-substituted anilines and N-[4[(5,7-diamino-3-phenylquinoxalin-2-yl)amino]benzoyl]-l-glutamic acid diethyl ester: evaluation of in vitro anti-cancer and anti-folate activities. *European Journal of Medicinal Chemistry*, **2008**, 43, 189-203	6.8	11
33	Optimizing cell permeation of an antibiotic resistance inhibitor for improved efficacy. *Journal of Medicinal Chemistry*, **2007**, 50, 5644-54	8.3	39
32	New thymidylate synthase inhibitors induce apoptosis in melanoma cell lines. *Toxicology in Vitro*, **2007**, 21, 240-8	3.6	8
31	Novel 3-benzoyl-2-piperazinylquinoxaline derivatives as potential antitumor agents. *Journal of Heterocyclic Chemistry*, **2006**, 43, 541-548	1.9	39
30	Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to Miltefosine by inhibiting drug efflux. *Antimicrobial Agents and Chemotherapy*, **2006**, 50, 3102-10	5.9	40
29	Antibacterial agent discovery using thymidylate synthase biolibrary screening. *Journal of Medicinal Chemistry*, **2006**, 49, 5958-68	8.3	22
28	Pharmacological and toxicological evaluation of a new series of thymidylate synthase inhibitors as anticancer agents. *Anticancer Research*, **2006**, 26, 3499-504	2.3	3
27	Structure-based optimization of a non-beta-lactam lead results in inhibitors that do not up-regulate beta-lactamase expression in cell culture. *Journal of the American Chemical Society*, **2005**, 127, 4632-9	16.4	53
26	Improving specificity vs bacterial thymidylate synthases through N-dansyl modulation of didansyltyrosine. *Journal of Medicinal Chemistry*, **2005**, 48, 913-6	8.3	16
25	The structure of Cryptococcus neoformans thymidylate synthase suggests strategies for using target dynamics for species-specific inhibition. *Acta Crystallographica Section D: Biological Crystallography*, **2005**, 61, 1320-34		9
24	Thymidylate synthase structure, function and implication in drug discovery. *Current Medicinal Chemistry*, **2005**, 12, 2241-58	4.3	79
23	Aza-boronic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 3979-83	2.9	12
22	The structural roles of conserved Pro196, Pro197 and His199 in the mechanism of thymidylate synthase. *Protein Engineering, Design and Selection*, **2003**, 16, 607-14	1.9	4
21	Quinoxaline chemistry. Part 15. 4-[2-Quinoxalylmethylenimino]-benzoylglutamates and -benzoates, 4-[2-quinoxalylmethyl-N-methylamino]-benzoylglutamates as analogues of classical antifolate agents. Synthesis, elucidation of structures and in vitro evaluation of antifolate and anticancer activities. *Il Farmaco*, **2003**, 58, 51-61		15

20	Inhibitor specificity via protein dynamics: insights from the design of antibacterial agents targeted against thymidylate synthase. *Chemistry and Biology*, **2003**, 10, 1183-93		28
19	ortho-Halogen naphthaleins as specific inhibitors of Lactobacillus casei thymidylate synthase. Conformational properties and biological activity. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 951-63	3.4	7
18	Structure-based studies on species-specific inhibition of thymidylate synthase. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2002**, 1587, 206-14	6.9	29
17	Structure-based design and in-parallel synthesis of inhibitors of AmpC beta-lactamase. *Chemistry and Biology*, **2001**, 8, 593-611		39
16	Predicting and harnessing protein flexibility in the design of species-specific inhibitors of thymidylate synthase. *Chemistry and Biology*, **2001**, 8, 981-95		25
15	Update on antifolate drugs targets. *Current Drug Targets*, **2001**, 2, 135-66	3	44
14	Structures and Reactivities of 1-Oxo-cycloalkan-2-ylideneacetic Acids. A 1H NMR, Modelling and Photochemical Study. *Tetrahedron*, **2000**, 56, 7561-7571	2.4	6
13	Structure-based discovery and in-parallel optimization of novel competitive inhibitors of thymidylate synthase. *Chemistry and Biology*, **1999**, 6, 319-31		97
12	Separation, structural determination and biological evaluation of the thymidylate synthase inhibitor 3,3-Di-(4?-hydroxyphenyl)-6(7)-chloro-1-oxo-1H,3H-naphtho[1,8-cd]pyran. *Journal of Heterocyclic Chemistry*, **1999**, 36, 1043-1048	1.9	8
11	Phthalein derivatives as a new tool for selectivity in thymidylate synthase inhibition. *Journal of Medicinal Chemistry*, **1999**, 42, 2112-24	8.3	21
10	Structure-based design of inhibitors specific for bacterial thymidylate synthase. *Biochemistry*, **1999**, 38, 1607-17	3.2	48
9	Quinoxaline chemistry. Part 11. 3-Phenyl-2[phenoxy- and phenoxymethyl]-6(7) or 6,8-substituted quinoxalines and N-[4-(6(7)-substituted or 6,8-disubstituted-3-phenylquinoxalin-2-yl)hydroxy or hydroxymethyl] benzoylglutamates. Synthesis and evaluation of in vitro anticancer activity and enzymatic inhibitory activity against dihydrofolate reductase and thymidylate synthase. *Il Farmaco*,		19
8	Thymidylate synthase inhibition: a structure-based rationale for drug design. *Medicinal Research Reviews*, **1998**, 18, 21-42	14.4	14
7	Asparagine 229 mutants of thymidylate synthase catalyze the methylation of 3-methyl-2Ŧdeoxyuridine 5Ŧmonophosphate. *Biochemistry*, **1996**, 35, 3944-9	3.2	2
6	Conformational analysis of phthalein derivatives acting as thymidylate synthase inhibitors by means of 1H NMR and quantum chemical calculations. *Bioorganic and Medicinal Chemistry*, **1996**, 4, 1783-94	3.4	13
5	Naphthalimido derivatives as antifolate thymidylate synthase inhibitors. *European Journal of Medicinal Chemistry*, **1996**, 31, 1011-1016	6.8	7
4	Theoretical analysis of the addition of hydroxylamine to uracil and 5-fluorouracil as a model for the thymidylate synthase reaction. *Computational and Theoretical Chemistry*, **1995**, 343, 1-9		4
3	A condensed thiadiazolo-pyrimidine as a new efficient fluorophore. Theoretical and experimental investigation of the electronic spectra and photophysics. *Journal of Photochemistry and Photobiology A: Chemistry*, **1994**, 77, 227-236	4.7	1

2	Cyclization reactions of 1,3-dibromopropan-2-ol, 2,3-dibromopropan-1-ol and 1-bromomethyloxirane with 6-amino-2,3-dihydro-2-thioxo-4(1H)-pyrimidinone. *Journal of Heterocyclic Chemistry*, **1991**, 28, 891-898	1.9	8
1	Theoretical study of electronic spectra and photophysics of uracil derivatives. *Photochemistry and Photobiology*, **1990**, 52, 361-74	3.6	18